910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)

Ezra E.W. Cohen, Robert L. Ferris, Amanda Psyrri, Robert I. Haddad, Makoto Tahara, Jean Bourhis, Kevin J. Harrington, P.M-H. Chang, JC Lin, M. Razaq, Margarida Teixeira, József Lövey, J. Chamois, A. Rueda Dominguez, Chaosu Hu, Mikhail Dvorkin, Steven De Beukelaer, Dmitri Pavlov, Holger Thurm, N. Lee

2020Annals of Oncology42 citationsDOI Open Access PDF

Topics & Concepts

MedicineAvelumabInterim analysisPlaceboClinical endpointInternal medicineDurvalumabHazard ratioSurgeryUrologyOncologyRandomized controlled trialCancerConfidence intervalPembrolizumabPathologyImmunotherapyAlternative medicineLymphoma Diagnosis and TreatmentHead and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

910O Primary results of the phase III JAVELIN head &amp; neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)

Topics & Concepts

910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)